Literature DB >> 19477286

Hammerhead ribozymes in therapeutic target discovery and validation.

Lorena Tedeschi1, Caterina Lande, Antonella Cecchettini, Lorenzo Citti.   

Abstract

Gene function assessment is a main task in biological networking investigations and system biology. High throughput technologies provide an impressive body of data that enables the design of hypotheses linking genes to phenotypes. When a putative scenario is depicted, gene knockdown technologies and RNA-dependent gene silencing are the most frequent approaches to assess the role of key effectors. In this paper, we discuss the relevance of hammerhead ribozymes in target discovery and validation, describing their properties and applications and highlighting their selectivity. In particular, similarities with siRNAs are presented and advantages and drawbacks are discussed. A description of the perspectives of ribozyme application in wide range studies is also provided, strengthening the value of these inhibitors for target validation purposes.

Mesh:

Substances:

Year:  2009        PMID: 19477286     DOI: 10.1016/j.drudis.2009.05.003

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  10 in total

Review 1.  Regulatory RNAs: charming gene management styles for synthetic biology applications.

Authors:  Jorge Vazquez-Anderson; Lydia M Contreras
Journal:  RNA Biol       Date:  2013-11-18       Impact factor: 4.652

Review 2.  The bright side of dark matter: lncRNAs in cancer.

Authors:  Joseph R Evans; Felix Y Feng; Arul M Chinnaiyan
Journal:  J Clin Invest       Date:  2016-08-01       Impact factor: 14.808

3.  Efficient inhibition of hepatitis B virus replication by hepatitis delta virus ribozymes delivered by targeting retrovirus.

Authors:  Chuan-Xi Wang; Yan-Qin Lu; Peng Qi; Long-Hua Chen; Jin-Xiang Han
Journal:  Virol J       Date:  2010-03-17       Impact factor: 4.099

4.  A strategy for developing a hammerhead ribozyme for selective RNA cleavage depending on substitutional RNA editing.

Authors:  Masatora Fukuda; Kei Kurihara; Yasuyoshi Tanaka; Masanobu Deshimaru
Journal:  RNA       Date:  2012-07-13       Impact factor: 4.942

5.  Selection of the most potent specific on/off adaptor-hepatitis delta virus ribozymes for use in gene targeting.

Authors:  Michel V Lévesque; Samuel G Rouleau; Jean-Pierre Perreault
Journal:  Nucleic Acid Ther       Date:  2011-07-08       Impact factor: 5.486

6.  Ribozyme-mediated gene knock down strategy to dissect the consequences of PDGF stimulation in vascular smooth muscle cells.

Authors:  Caterina Lande; Claudia Boccardi; Lorenzo Citti; Alberto Mercatanti; Milena Rizzo; Silvia Rocchiccioli; Lorena Tedeschi; Maria Giovanna Trivella; Antonella Cecchettini
Journal:  BMC Res Notes       Date:  2012-07-10

7.  Improved design of hammerhead ribozyme for selective digestion of target RNA through recognition of site-specific adenosine-to-inosine RNA editing.

Authors:  Masatora Fukuda; Kei Kurihara; Shota Yamaguchi; Yui Oyama; Masanobu Deshimaru
Journal:  RNA       Date:  2014-01-21       Impact factor: 4.942

8.  Therapeutic targeting of noncoding RNAs in hepatocellular carcinoma: Recent progress and future prospects.

Authors:  Zhangang Xiao; Jing Shen; Lin Zhang; Mingxing Li; Wei Hu; Chihin Cho
Journal:  Oncol Lett       Date:  2018-01-09       Impact factor: 2.967

Review 9.  The application of ribozymes and DNAzymes in muscle and brain.

Authors:  Nikolaos P Mastroyiannopoulos; James B Uney; Leonidas A Phylactou
Journal:  Molecules       Date:  2010-08-09       Impact factor: 4.411

10.  Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy.

Authors:  Chi Han Li; Yangchao Chen
Journal:  Curr Genomics       Date:  2015-10       Impact factor: 2.236

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.